Huntington's Disease Market Size, Share, Growth Insights Report 2023-2030

Huntington's Disease Market Overview

Global Huntington's Disease Market Poised for Significant Growth According to Latest Report

The global Huntington's Disease Market is projected to experience substantial growth at a high Compound Annual Growth Rate (CAGR) during the forecast period from 2023 to 2030, as outlined in a comprehensive market overview.

Huntington's disease, an inherited neurodegenerative disorder impacting nerve cells in the central nervous system, manifests in movement and cognitive impairments. With symptoms typically appearing between the ages of 30 and 40, the disease significantly affects the functional abilities of individuals. In the case of onset before the age of 20, it is referred to as juvenile Huntington's disease. Both men and women are susceptible to this condition.

Key Market Metrics:

CAGR: High

Forecast Period: 2023-2030

Data Availability: Value (US$)

Segments Covered: Diagnosis, Drug/Therapy, Distribution Channel, and Region

Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region: Asia-Pacific

Largest Region: North America

Insights Covered in the Report:

• Competitive Landscape Analysis
• Company Profile Analysis
• Market Size, Share, Growth
• Demand and Recent Developments
• Mergers and Acquisitions
• New Product Launches
• Growth Strategies
• Revenue Analysis
• Porter’s Analysis
• Pricing Analysis
• Regulatory Analysis
• Supply-Chain Analysis
• Other Key Insights

To know more Insights Download Sample:

Huntington's Disease Market Dynamics:

The market is bolstered by the development of extensive pipeline drugs, including UniQure's AMT-130, PTC Therapeutics' PTC518, Sage Therapeutics' Sage-718, Annexon Biosciences' ANX-005, and Azevan Pharmaceuticals' SRX246. These innovative therapies aim to address the diverse symptoms of Huntington's disease, contributing to the market's anticipated growth. Factors such as increased demand for advanced disease treatment, rising awareness of chronic diseases, and ongoing drug discoveries are further propelling the market.

However, challenges arise from the termination of clinical trials, with only Tetrabenazine and deutetrabenazine currently approved for treating chorea. The unexpected termination of trials, as seen with Novartis' Branaplam, underscores the need for continued research to bring novel treatments to market.

Segment Analysis:

The global Huntington’s disease market is segmented based on drug class, distribution channel, and region. Notably, the Deutetrabenazine Drug/Therapy segment accounts for a significant market share, with drugs such as Xenazine (tetrabenazine) and Austedo (deutetrabenazine) gaining FDA approval for treating chorea.

Geographical Analysis:

North America leads the market, holding a substantial share in 2022. The region's dominance is attributed to a robust drug pipeline, the prevalence of Huntington’s disease, and increasing clinical trials. According to the Journal of Neurology Research, the worldwide prevalence of Huntington's disease is estimated at 5-10 cases per 100,000 inhabitants, with an equal distribution between men and women.

Competitive Landscape:

Key players in the Huntington's disease market include Teva Pharmaceuticals, Apotex Corporation, Pfizer, Rosemont Pharma, Agnito Pharma, Merck & Co, Eli Lilly Company, Ralington Pharma, Par Pharmaceutical, and Accord Healthcare, among others.

Related Reports:

Water for Injection Market

Spinal Stenosis Treatment Market

Ziprasidone Market

Cri-du-chat Syndrome Market

Keratosis Pilaris Treatment Market

Short Bowel Syndrome Market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Name: Sai K

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com